ERBB2 and breast cancer: Triple-negative breast cancer (TNBC), which can be referred to as the tumors that display absence of estrogen receptor (ER) and progesterone receptor (PR) without the overexpression of human epidermal growth factor receptor 2 (HER2), accounts for 15–20% of breast cancer [2, 3].